Safety of anti-VEGF drugs with trabeculectomy for neovascular glaucoma

International Eye Science

Volumn 16, Issue 5, 2016, Pages 837-840

  Wang, Fei ^a   Wang, Li Lun ^a  

^a YAN'AN UNIVERSITY   (China)

Author keywords

Anti vascular endothelial growth factor drugs; Intraocular pressure; Neovascular glaucoma; Ranibizumab; Visual acuity

Indexed keywords

RANIBIZUMAB;

ARTICLE; CONTROLLED STUDY; CRYOTHERAPY; DRUG SAFETY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; NEOVASCULAR GLAUCOMA; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; TRABECULECTOMY; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84968542753     PISSN: 16725123     EISSN: None     Source Type: Journal    
DOI: 10.3980/j.issn.1672-5123.2016.5.11     Document Type: Article

References (2)

1. Yu XB, Sun XH, Dahan E. Increased levels of transforming growth factor-betal and- beta2 in the aqueous humor of patients with neovascular glaucoma. Ophthalmic Surg Lasers Imag 2007; 38(1):6-14
2. Grover S, Gupta S, Sharma R. Intracameralbevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009; 93(2):273-274